INS and type 2 diabetes mellitus: A number of studies have shown that, in postoperative patients with T2D, GLP-1 receptor (GLP-1R) blockade with the GLP-1R antagonist Exendin9 causes significant reduction of insulin secretion when compared to a control group with lower GLP-1 levels, indicating an effect on β-cell function62,63.